Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum.
We report successful treatment of a refractory myelodysplastic syndrome-associated pyoderma gangrenosum with the combination of thalidomide and interferon-alpha2a in a single patient. A non-healing wound developed on a 40-year-old woman's left thumb after minor trauma. Massive ulcerovegetative lesions developed after reconstruction surgery. Histopathological examination of the bone marrow and cytogenetic studies revealed an atypical myeloproliferative/myelodysplastic syndrome. The skin lesions resolved dramatically after two months of thalidomide and interferon-alpha2a combination therapy and the haematological status improved.
Koca
E
E
Department of Internal Medicine, Division of Haematology, Hacettepe University Medical School, Turkey. ekoca@hacettepe.edu.tr
Duman
A E
AE
Cetiner
D
D
Buyukasik
Y
Y
Haznedaroglu
I C
IC
Uner
A
A
Demirhan
B
B
Kerimoglu
U
U
Barista
I
I
Calguneri
M
M
Ozcebe
O I
OI
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology*; D011994:Recombinant Proteins; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013792:Thalidomide